Immunohistochemical PSMA expression patterns of primary prostate cancer tissue are associated with the detection rate of biochemical recurrence with
Aged
Androgen Antagonists
/ therapeutic use
Antigens, Surface
/ metabolism
Biomarkers, Tumor
/ metabolism
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Glutamate Carboxypeptidase II
/ metabolism
Humans
Male
Middle Aged
Neoplasm Recurrence, Local
/ diagnostic imaging
Oligopeptides
/ metabolism
Positron Emission Tomography Computed Tomography
/ methods
Prostate-Specific Antigen
/ blood
Prostatic Neoplasms
/ diagnostic imaging
Radiopharmaceuticals
/ metabolism
Retrospective Studies
PSMA PET
PSMA staining
PSMA-negative prostate cancer
immunohistochemistry
restaging
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
02
2020
accepted:
19
04
2020
entrez:
3
6
2020
pubmed:
3
6
2020
medline:
19
5
2021
Statut:
epublish
Résumé
Prostate-specific membrane antigen (PSMA) targeted PET has a high detection rate for biochemical recurrence (BCR) of prostate cancer (PCa). Nevertheless, even at high prostate-specific antigen (PSA) levels (> 3 ng/ml), a relevant number of PSMA-PET scans are negative, mainly due to PSMA-negative PCa. Our objective was to investigate whether PSMA-expression patterns of the primary tumour on immunohistochemistry (IHC) are associated with PSMA-PET detection rate of recurrent PCa.
Identifiants
pubmed: 32483440
doi: 10.7150/thno.44584
pii: thnov10p6082
pmc: PMC7255040
doi:
Substances chimiques
Androgen Antagonists
0
Antigens, Surface
0
Biomarkers, Tumor
0
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Prostate-Specific Antigen
EC 3.4.21.77
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6082-6094Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing Interests: IAB has received research grants and speaker honorarium from GE Healthcare, research grants from Swiss Life and speaker honorarium from Bayer Health Care and Astellas Pharma AG. MM received speaker fees from GE Healthcare. TH holds an advisory function for MSD and Bayer. Authors DAF, JHR, UJM, BK, JM, LH, DE, and NJR declare no conflict of interest. The Department of Nuclear Medicine holds an institutional Research Contract with GE Healthcare. The authors thank the Sick legat and the Iten-Kohaut foundation for their financial support.
Références
J Nucl Med. 2017 Oct;58(10):1617-1623
pubmed: 28408531
Pract Radiat Oncol. 2018 Jan - Feb;8(1):28-39
pubmed: 29037965
Radiographics. 2018 Jan-Feb;38(1):200-217
pubmed: 29320333
J Natl Cancer Inst. 1998 May 20;90(10):766-71
pubmed: 9605647
Clin Nucl Med. 2018 Jun;43(6):e186-e188
pubmed: 29659383
Eur Urol. 2019 Oct;76(4):469-478
pubmed: 31345636
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Sci Rep. 2018 Mar 9;8(1):4254
pubmed: 29523813
BJU Int. 2019 Sep;124(3):401-407
pubmed: 31141284
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
Urol Oncol. 1995 Jan-Feb;1(1):18-28
pubmed: 21224086
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Hum Pathol. 2007 May;38(5):696-701
pubmed: 17320151
J Urol. 2016 May;195(5):1436-1443
pubmed: 26682756
Prostate. 2018 Jul;78(10):758-765
pubmed: 29633296
J Nucl Med. 2018 Feb;59(2):238-243
pubmed: 28775203
Eur Urol. 2009 Apr;55(4):876-83
pubmed: 19101076
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
Theranostics. 2016 Jun 18;6(10):1619-28
pubmed: 27446496
Cancer. 1998 Jun 1;82(11):2256-61
pubmed: 9610707
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
Clin Cancer Res. 2003 Dec 15;9(17):6357-62
pubmed: 14695135
Ann Nucl Med. 2018 Oct;32(8):523-531
pubmed: 29982989
Clin Cancer Res. 1997 Jan;3(1):81-5
pubmed: 9815541
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):889-900
pubmed: 30488099
J Nucl Med. 2019 Sep;60(9):1270-1276
pubmed: 30737300
J Nucl Med. 2019 Jun;60(6):794-800
pubmed: 30442757
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):941-949
pubmed: 28138747
Eur Urol. 2016 Jul;70(1):106-119
pubmed: 26996659
Urology. 1998 Oct;52(4):637-40
pubmed: 9763084
Front Oncol. 2018 Dec 20;8:623
pubmed: 30619757
Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):4-11
pubmed: 28894899
Prostate. 2011 Feb 15;71(3):281-8
pubmed: 20809553
J Nucl Med. 2017 Dec;58(12):1972-1976
pubmed: 28747524